Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | MMP8 | P22894 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591452 | 1.00 | RPS6KA3 (0.50) | RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL4135759 | 0.85 | DYRK1A (0.49) | RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL782851 | 0.85 | RPS6KA3 (0.64) | RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL30637065 | 0.78 | MAPKAPK2 (0.50) | RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL9228663 | 0.78 | MAPKAPK2 (0.50) | RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL12178204 | 0.78 | MAPKAPK2 (0.74) | RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL706055 | 0.78 | MAPKAPK2 (0.50) | RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL18211315 | 0.78 | MAPKAPK2 (0.50) | RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL2619124 | 0.78 | MAPKAPK2 (0.50) | RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL31214307 | 0.77 | RPS6KA3 (0.53) | RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108926-B | Intermediate compound for preparing erdasatinib and preparation method | 上海工程技术大学 | 2023-06-20 | — | — | CN | claimed |
| CN-115108926-A | Intermediate compound for preparing erdastinib and preparation method | 上海工程技术大学 | 2022-09-27 | — | — | CN | claimed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-116535389-B | 6-Pyridine-3-quinoxaline urea derivative and application thereof | 四川大学 | 2024-05-03 | — | — | CN | disclosed |
| US-20240116880-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2024-04-11 | — | — | US | disclosed |
| WO-2024026076-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | SEPTERNA, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-116887833-A | Certain chemical entities, compositions and methods | 润新生物公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4255434-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-116535389-A | 6-pyridine-3-quinoxaline urea derivative and application thereof | 四川大学 | 2023-08-04 | — | — | CN | disclosed |
| CN-115108926-B | Intermediate compound for preparing erdasatinib and preparation method | 上海工程技术大学 | 2023-06-20 | — | — | CN | disclosed |
| EP-1723146-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2005092894-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-0518530-B1 | Improvements in or relating to excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5196421-A | Treatment of neurological disorders | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0518530-A2 | Improvements in or relating to excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1992-12-16 | — | — | EP | disclosed |
| US-5153196-A | Administering for reduction of neurotransmission in nervous system disorders | ELI LILLY AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116880-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, RB1 | RPS6KA3 3411/4885MAPKAPK2 4485/4885CSNK2A1 2341/4885 |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | RPS6KA3 998/4885MAPKAPK2 134/4885CSNK2A1 312/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | RPS6KA3 287/4885MAPKAPK2 1389/4885CSNK2A1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.